PUBLISHER: TechSci Research | PRODUCT CODE: 1879359
PUBLISHER: TechSci Research | PRODUCT CODE: 1879359
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Nuclear Pharmacy Market, valued at USD 5.99 Billion in 2024, is projected to experience a CAGR of 7.92% to reach USD 9.46 Billion by 2030. Nuclear pharmacy involves the preparation and dispensing of radioactive materials for patient administration in nuclear medicine, utilizing radiopharmaceuticals for diagnostic and therapeutic purposes. Market growth is driven by the increasing prevalence of chronic diseases like cancer and cardiovascular disorders, advancements in nuclear medicine technologies, and a growing demand for personalized medicine, expanding applications across oncology and neurology.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 5.99 Billion |
| Market Size 2030 | USD 9.46 Billion |
| CAGR 2025-2030 | 7.92% |
| Fastest Growing Segment | Institutional |
| Largest Market | North America |
Key Market Drivers
The global nuclear pharmacy market is significantly influenced by two major driving factors: the rising burden of chronic diseases and continuous advancements in radiopharmaceutical development. The increasing global burden of chronic diseases represents a primary impetus for the nuclear pharmacy market, necessitating sophisticated diagnostic and therapeutic interventions. Conditions like cancer, cardiovascular disorders, and neurodegenerative diseases exhibit growing prevalence worldwide, driving escalating demand for early, accurate detection and targeted treatment. Nuclear medicine, offering functional and molecular imaging, proves crucial in disease staging, treatment monitoring, and personalized therapy selection.
Key Market Challenges
A significant challenge impeding the Global Nuclear Pharmacy Market's growth is the persistent supply chain disruptions and shortages of critical radioisotopes. The inherently short half-lives of these materials, such as Technetium-99m, necessitate complex and highly efficient logistics, making the supply chain exceptionally vulnerable to any interruption in production or distribution. This reliance on a limited number of aging nuclear reactors for isotope generation, coupled with unpredictable maintenance schedules or unexpected outages, frequently leads to insufficient supply.
Key Market Trends
The emergence of targeted alpha therapies significantly influences the global nuclear pharmacy market by introducing a potent and precise cancer treatment modality. These therapies deliver highly localized radiation using alpha-emitting isotopes, effectively targeting malignant cells with minimal damage to healthy tissues, thus expanding therapeutic options. In January 2025, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) strategy meeting indicated two-thirds of physicians anticipated over 10% growth in therapy at their facilities within the year. This is reinforced by Sanofi's AlphaMedix (Lead-212-DOTAMTATE) receiving FDA Breakthrough Therapy Designation in February 2024, followed by positive Phase 2 results for gastroenteropancreatic neuroendocrine tumors in October 2025.
In this report, the Global Nuclear Pharmacy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Nuclear Pharmacy Market.
Global Nuclear Pharmacy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: